Swiss Consensus Statement: Recommendations for Optimising Re-Treatment With MabThera® (rituximab) in Rheumatoid Arthritis. Swiss Med Wkly 2010, 140 (2728), w13073. https://doi.org/10.4414/smw.2010.13073.